Skip to main content
PortfolioRapha Capital Management

AsclepiX Therapeutics, Inc. Strengthens Board of Directors, Welcomes Steven Altschuler, MD

By March 25, 2019February 4th, 2021No Comments

AsclepiX Therapeutics
AsclepiX Therapeutics, Inc. Strengthens Board of Directors, Welcomes Steven Altschuler, MD

  • AsclepiX Therapeutics, Inc., a biopharmaceutical company focused on developing novel peptide therapies, including AXT107 for retinal disease and novel peptides for cancer, adds Steven Altschuler, MD to Board of Directors.
  • Dr. Altschuler, the founder and Chairman of the Board of Spark Therapeutics Inc. (NASDAQ: ONCE), brings to AsclepiX a deep knowledge and experience in developing novel therapies for the treatment of retinal disease.
March 25, 2019